Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman by Simona Gurzu et al.
Gurzu et al. Diagnostic Pathology 2013, 8:150
http://www.diagnosticpathology.org/content/8/1/150CASE REPORT Open AccessLethal cardiotoxicity, steatohepatitis, chronic
pancreatitis, and acute enteritis induced by
capecitabine and oxaliplatin in a 36-year-old
woman
Simona Gurzu1*, Ioan Jung1, Maria Comsulea1, Zoltan Kadar2, Leonard Azamfirei3 and Calin Molnar4Abstract
A 36-year-old female was hospitalized with symptoms suggesting intestinal occlusion. She was diagnosed with
adenocarcinoma of the ampulla of Vater (pT4N0 stage) and underwent cephalic duodenopancreatectomy 8 months
ago. Five cycles of postoperative chemotherapy were administrated using capecitabine and oxaliplatin (CAPOX or
XELOX), the last one being completed 1 month ago. During the present hospitalization, because of normal
computed tomography and ultrasound abdominal examination, rehydration and antibiotherapy were administrated.
However, 4 days after hospital admission, the patient died. At autopsy and histological examination, we found a
severe myocardial sclerosis with large scarring areas, severe steatohepatitis, chronic pancreatitis with large fibrotic
areas, and acute enteritis. Alcohol consumption was denied. The patient died due to associated heart, liver and
pancreatic failure. This multiorgan toxicity and death following CAPOX regimen had not yet been reported in the
literature.
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In advanced gastrointestinal (GI) cancers, an associa-
tion between cytotoxic drugs and biological agents is
usually used. The biological agents such as bevacizumab,
cetuximab, and panitumumab seem to be well tolerated
and exhibit promising results, but their cost-effectiveness
has been seriously evaluated in the literature. Bevacizu-
mab, an antiangiogenic drug, was approved by the Food
and Drug Administration (FDA) in 2004 for the treatment
of colorectal carcinoma. Cetuximab and panitumumab,
the anti-EGFR (epidermal growth factor) agents, can also
be used in case of GI tumors that do not display K-ras
mutation [1]. However, these agents cannot be used alone
but only associated with classical chemotherapeutics, and* Correspondence: simonagurzu@yahoo.com
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reproduction in any medium, provided the orhave been approved only for metastatic cases, with the ad-
juvant protocol for locally advanced cancer being ques-
tionable [1].
In most of the GI locally advanced or metastatic tu-
mors, cytotoxic drugs such as irinotecan, oxaliplatin,
5-fluorouracil (5-FU), and capecitabine are used as first-
line therapy [1,2]. Oxaliplatin was approved by the FDA
in 2002 for the treatment of Stage III/IV (Dukes’ C/D)
colorectal carcinoma [2], but it is also used in other
adenocarcinomas of the GI tract. Depending on the
patient’s functional status and comorbidities, different
combination regimens are used, such as FOLFIRI (5-FU,
leucovorin [folinic acid], irinotecan), FOLFOX (5-FU,
leucovorin [folinic acid], oxaliplatin), and GEMOX (gem
citabine, oxaliplatin); in addition, monotherapy treat-
ments are also utilized (5-FU, gemcitabine, capecitabine)
[1-3]. As some clinical trials revealed significant cardio-
toxicity in case of intravenous 5-FU, when comparedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and similar or superior efficacy in case of capecitabine,
the oral administration of capecitabine is preferred in as-
sociation with oxaliplatin (XELOX or CAPOX) [2-5].
In locally advanced cases, at least two problems should
be taken into account. On the one hand, the predictive
criteria are not well defined, with the microsatellite sta-
tus or immunostaining being more valuable as prognos-
tic than predictive factors [6]. On the other hand, despite
the benefits of adjuvant therapy, its dose-dependent in-
creased toxicity and costs should also be taken into ac-
count to select patients who are likely to benefit from
them [1]. In this study, we present a multiorgan fatal
chemotherapy toxicity, in a 36-year-old female suffering
from locally advanced adenocarcinoma of the ampulla of
Vater. In addition, with regard to the rarity of this lesion, a
review of the relevant literature regarding chemoterapy-
induced toxicity has been carried out.
Case presentation
A 36-year-old cachectic female (body weight was 41.2 kg
and height was 1.62 m), previously diagnosed with adeno-
carcinoma of the ampulla of Vater that invades the pancreas
(pT4N0 stage), which was surgically removed (cephalic
duodenopancreatectomy, radical surgery) 8 months ago,
was admitted to our hospital with pale skin, scleral jaun-
dice, sudden onset of severe abdominal pain and cramping,
vomiting, diarrhea, and subfebrility. No alcohol, tobacco,
or other drug use was declared. Before and after surgery
and also before adjuvant therapy, no comorbidities were di-
agnosed, and the general status was carefully assessed with-
out modification. Two months following surgery, she
underwent five chemotherapy cycles with a combined regi-
men that included oral capecitabine and intravenous
oxaliplatin (CAPOX or XELOX). CAPOX regimen com-
prised administration of 150 mg/m2 of oxaliplatin (diluted
in a 5% glucose solution) intravenously over 120 min on
Day 1, and then 1250 mg/m2 of oral capecitabine adminis-
tered twice daily from Days 1 to 14, followed by 1-week
drug holiday, in a 21-day cycle. The last (fifth) cycle was
stopped 1 month before the present admission. The reason
for choosing this aggressive regimen was the patients’ age
and good pre-chemotherapy general status. There were no
significant acute toxicity-related disorders, except slight
diarrhea and vomiting, either of which recurred before this
episode.
During the present admission, on physical examin-
ation, when palpating the abdomen, generalized abdom-
inal tenderness with voluntary guarding was observed,
with hypoactive bowel sounds. Considering her symp-
toms that suggested a tumor relapse, we decided to
perform an emergency GI endoscopy that did not
evidence tumor relapse or intestinal obstruction. The
abdominal-computed tomography and ultrasound werenormal. Her serology showed slight anemia (hemoglobin:
10 g/dl, hematocrit: 40%), thrombocytopenia (114,000
platelets/μl), leukocytosis (86.8% neutrophils and 11.5%
lymphocytes), and elevated levels of amylase (147 U/L),
total bilirubin (6.26 mg/dl), transaminases (aspartate
transaminase [AST]: 56 U/L and alanine transaminase
[ALT]: 40 U/L), and lactate dehydrogenase (484 U/L).
Her glycemia was in normal limits (78 mg/dl). Electro-
cardiogram showed a slightly sinusal tachycardia and
T-wave inversion. Adapted diet, bowel rest, antibiotherapy,
and intravenous hydration were administrated, but the
patient died 4 days after admission.
At necropsy, gross and histopathological examination
revealed acute non-specific enteritis, chronic pancreatitis
with large fibrotic areas and atrophy of the pancreatic
parenchyma, and severe steatohepatitis (Figure 1). Most
of the hepatocytes were transformed into fatty hepato-
cytes, the portal spaces were dilated and fibrotic, and the
fibrosis was also intralobullary. Within the fibrotic areas,
several billiary channels were observed that were marked
by keratin 7. The hepatocytes that were connected
to the fibrotic septa were also positive at keratin 7
(Figure 1). No vascular changes such as fibrosis of sinu-
soids and/or veins necrosis of the central hepatocytes
were noted. Besides these disorders, fibrinous pericardi-
tis, hydropericardium (300 ml of serous fluid), bilateral
hydrothorax (200 ml of serous fluid on both the parts),
ascites (400 ml of serous fluid), scleral jaundice, lung
dystelectasis with hyaline membranes (Acute Respiratory
Distress Syndrome) (Figure 2), and shock kidney were
also observed. No tumor recurrences, either node-
positive or distant metastases, were evidenced.
A particular histopathological aspect was also ob-
served in the myocardium. Severe diffuse myocardial
fibrosis was present in both right and left ventricles, in
subendocardial and subpericardial areas (Figure 2).
No coronarosclerosis or myocardium hypertrophy was
evidenced. The heart weighted 365 g. Her cardiac func-
tion was normal before chemotherapy.
Based on the macro- and microscopic features, it was
decided that the death was caused by multiorgan failure
syndrome, with the main lesion being the chemothe-
rapy-induced cardiotoxicity. The patient’s age, absence
of coronarosclerosis or myocardium hypertrophy, and
the associated-hepatic and pancreatic lesions proved that
the myocardial disorders had toxic and non-ischemic
etiology.
Discussion
Adenocarcinomas of the ampulla of Vater are very rare ma-
lignant tumors of the GI tract. They are usually diagnosed in
locally advanced or metastatic stages. Being rare tumors, the
optimal first-line therapy has not yet been elucidated. One of
the commonest first-line chemotherapeutics association is
Figure 1 CAPOX-associated toxicity is characterized by steatohepatitis (A-D) and chronic fibrous pancreatitis (E-F).
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or XELOX) [4].
Capecitabine is a pro-drug of the cytotoxic agent 5-FU
which can be orally administrated and can release FU dir-
ectly at the tumor site due to increased activity of thymi-
dine phosphorylase in tumor cells, when compared with
normal healthy ones, and most of the researchers admit
that it presents a favorable side-effect profile [5,7]. How-
ever, some toxic effects have been reported such as
hand-foot syndrome or palmar-plantar erythrodyses
thesia (painful fingers and toes), diarrhea, nausea, vomiting,
and mucositis [4,5,8]. In about 60 studies reported to date,
cardiotoxicity was infrequently observed, occurring in
1-18% of the cases, being displayed as angina (70%),
arrhythmia (10%), myocardial infarction (10%), or car-
diogenic shock (10%), without remission after dose reduc-
tion or additional medical prophylaxis [9,10]. About 11% ofthe patients with capecitabine-associated cardiotoxicity were
reported to have died [10]. To date, about 25 cases with
capecitabine-related hypertriglyceridemia have been reported
[5,8], and three of them also presented capecitabine-induced
acute necrotizing pancreatitis that required interruption of
capecitabine therapy [5,7,8,11]. The pathogenesis of pancrea-
titis is not well elucidated, and some researchers have
mentioned that capecitabine may reduce the activity of
lipoprotein lipase and hepatic triglyceride lipase [5,8,12].
Pancreatitis can also be caused by surgery or the tumor lo-
cation, such as in the reported case. However, no signs of
pancreatitis were detected in our patient before this epi-
sode. It has also been suggested that the atherosclerotic
risk could increase in patients treated with capecitabine
over a 6-month period; however, adjuvant administration
of fenofibrate could normalize the serum level of triglycer-
ides [8]. In the present case, the patient had chronic
Figure 2 CAPOX regimen is associated with severe myocardial fibrosis (A-C) and pulmonary hyaline membranes (D).
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the pancreatic parenchyma, without atherosclerosis, after
five chemotherapy cycles of capecitabine-based regimen.
Oxaliplatin is a third-generation platinum-based alkylat-
ing agent that inhibits DNA synthesis in cancer cells [3].
Its side effects mainly include sensory peripheral neur-
opathy, followed by fatigue, stomatitis, nausea, vomiting,
diarrhea, pulmonary fibrosis, gastrointestinal and liver tox-
icity, ototoxicity, and nephrotoxicity [3,4,13]. The main
hepatotoxic features are steatohepatitis, steatosis, and
vascular changes displayed as fibrosis of sinusoids as
well as central veins and necrosis of the central hepatocytes
(sinusoidal obstruction syndrome) [13]. Steatohepatitis
without vascular changes was evidenced in our case.
Hepatotoxicity seems to be particularly present after
more than six cycles of systemic chemotherapy, prob-
ably due to increased oxidative stress and direct effect
of endotoxins; however, it could rather be a postopera-
tive morbid effect and may not have led to the patient’s
death [13]. Hepatotoxicity could be prevented through
supplementation of AdoMet (S-adenosylmethionine) in
patients treated with oxaliplatin-based regimen [14], prob-
ably by increasing the activity of DNA methyltransferases
[15]. To date, only one study has reported the pos-
sible oxaliplatin-related acute pancreatitis in six GI
tumors [3].
In case of CAPOX, the eligible patients should have a
good performance status. According to Overman et al.
(2009), patients with granulocytopenia (<1.500 granu
locytes/mm3), thrombocytopenia (<100.000 platelets/
mm3), and severe anemia (hemoglobin<10 mg/dl) arenot eligible [4]. Cardiac disease, brain metastases, renal
function impairment (creatinine clearance <30 ml/min),
and liver failure (total bilirubin>1.5 mg/dl, albumin>2.5
mg/dl, and elevated levels of transaminases) are also exclu-
sion criteria [4], although some researchers have proved
that the combination of oxaliplatin and capecitabine could
also be tolerated in patients with hyperbilirubinemia and
hepatic dysfunctions, respectively [16].
In one of the largest prospective phase II clinical stud-
ies performed with CAPOX in cases of adenocarcinomas
of the small bowel and ampulla of Vater, the following
related toxicities were observed: fatigue, peripheral
neuropathy, nausea, diarrhea, hand-foot syndrome, and
hematologic disorders such as neutropenia, anemia, and
thrombocytopenia. The researchers proved that CAPOX
regimen was well tolerated and highly effective, with an
overall response rate of 50% and no treatment-related
deaths [4]. Other rare lesions, such as cerebral infarc-
tion, stomatitis, hypomagnesemia, hyperbilirubinemia,
hyperglycemia, and hypocalcemia were also reported to
be associated with combination regimen of capecitabine
and oxaliplatin [8,16]. To our knowledge, no cases
with CAPOX-induced chronic pancreatitis have been
reported till date, and in only three cases, ileitis occurred
in patients with metastatic colorectal carcinomas treated
with oxaliplatin, capecitabine, and bevacizumab [17].
It must be noted that in the case presented in this
study, the CAPOX regimen was highly effective, with-
out relapses and/or metastases; however, fatal signs of
toxicity occurred 1 month after completion of the five cy-
cles. Even in young patients with a good performance status,
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as well as pancreatitis should be taken in account.
Conclusions
Although chemotherapeutics toxicity is a well-known
adverse drug reaction, any toxicity should be carefully
approached and widely disseminated, to increase general
knowledge. The particularity of this case was the
multiorgan toxicity that occurred in a young female with
a pT4N0-staged carcinoma of the ampulla of Vater
treated with questionable maximum dose of XELOX
regimen. These fatal toxic associations highlight the
necessity of establishing new standardized predictive
criteria for postoperative oncological management of
non-metastatic locally advanced cancers of the intestine
and colon segments, according to gender and functional
status, which will be applicable in clinical practice.
Consent
Written informed consent was obtained from the pa-
tient’s relatives for publication of this Case Report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
Abbreviations
ALT: Alanine transaminase; AST: Aspartate transaminase; CAPOX or
XELOX: Therapetic regimen that associates oral administration of capecitabine
and oxaliplatin; EGFR: Epidermal growth factor; FDA: Food and Drug
Administration; FOLFIRI: Therapetic regimen that associates 5-fluorouracil (5-FU)
leucovorin [folinic acid], and irinotecan; FOLFOX: Therapetic regimen that
associates 5-FU, leucovorin, and oxaliplatin; GEMOX: Therapetic regimen that
associates gemcitabine and oxaliplatin; GI: Gastrointestinal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SG wrote the manuscript and carried out the study design. IJ coordinated
the study design and the draft the manuscript and carried out the
interpretation of the data from literature. MC carried out the histological
examination and immunoassays. ZK carried out the oncological
management and interpretation of oncological data. LA participated in the
interpretation of clinical data. CM carried out the surgical intervention and
follow-up and supervised the study design. All authors read and approved
the final manuscript.
Acknowledgements
The English-language manuscript was polished by SPI Global Professional
Editing Service.
Author details
1Department of Pathology, University of Medicine and Pharmacy of
Tirgu-Mures, Tirgu-Mures, Romania. 2Department of Oncology, County
Hospital of Tirgu-Mures, Tirgu-Mures, Romania. 3Intensive Care Unit,
University of Medicine and Pharmacy of Tirgu-Mures, Tirgu-Mures, Romania.
4Department of Surgery, University of Medicine and Pharmacy of Tirgu-
Mures, Tirgu-Mures, Romania.
Received: 1 May 2013 Accepted: 26 August 2013
Published: 16 September 2013References
1. Dekanic A, Dintinjan RD, Budisavljevic I, Pecanic S, Butorac MZ, Jonic N: Strong
nuclear EGFR expression in colorectal carcinomas is associated with cyclin-
D1 but not with gene EGFR amplification. Diagn Pathol 2011, 6:108.
2. Cartwright TH: Treatment decision after diagnosis of metastatic colorectal
cancer. Clin Colorectal Cancer 2012, 11:155–166.
3. Butt W, Saadati H, Saif MW: Oxaliplatin-induced pancreatitis: a case series.
Anticancer Res 2010, 30:5113–5116.
4. Overman MJ, Varadhachary GR, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese
JL, Wolff RA: Phase II study of capecitabine and oxaliplatin for advanced
adenocarcinoma of the small bowell and ampulla of Vater. J Clin Oncol
2009, 27:2598–2603.
5. Chan HY, Ng CM, Tiu SC, Chan AOK, Shek CC: Hypertrigliceridaemia-
induced pancreatitis: a contributory role of capecitabine?
Hong Kong Med J 2012, 18:526–529.
6. Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J:
Associations of beta-catenin alterations and MSI screening status with
expression of key cell ceycle regulating proteins and survival form
colorectal cancer. Diagn Pathol 2013, 8:10.
7. Yucel H, Warmerdam LV: Capecitabine-induced pancreatitis. J Oncol Pharm
Pract 2010, 16:133–134.
8. Michie CO, Sakala M, Rivans I, Strachan MWJ, Clive S: The frequency and
severity of capecitabine-induced hypertriglyceridaemia in routine clinical
practice: a prospective study. Br J Cancer 2010, 103:617–621.
9. Y-Hassan S, Tornvall P, Tornerud M, Henareh L: Capecitabine caused
cardiogenic shock through induction of global takotsubo syndrome.
Cardiovasc Revasc Med 2013, 14:57–61.
10. Manojlovic N, Babic D, Stojanovic S, Filipovic I, Radoje D:
Capecitabine cardiotoxicity - case reports and literature review.
Hepatogastroenterology 2008, 55:1249–1256.
11. Jones KL, Valero V: Capecitabine-induced pancreatitis. Pharmacotherapy
2003, 23:1076–1078.
12. Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J,
Deliconstantinos G: Capecitabine (Xeloda) as monotherapy in
advanced breast and colorectal cancer: effectiveness and side-effects.
Anticancer Res 2007, 27:1653–1656.
13. Pessaux P: Chemotherapy’s hepatotoxicity: what is the impact on
surgery? J Chir (Paris) 2010, 147(Suppl 1):S7–S11.
14. Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G:
The role of S-adenosylmethionine in preventing oxaliplatin-induced
liver toxicity: a retrospective analysis in metastatic colorectal cancer
patients treated with bevacizumab plus oxaliplatin-based regimen.
Support Care Cancer 2012, 20:135–139.
15. Luo S, Zhang X, Yu M, Yan H, Liu H, Wilson JH, Huang G: Folic acid acts
through DNA methyltransferases to induce the differentiation of neural
stem cells into neurons. Cell Biochem Biophys 2013, 66:559–566.
16. Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT,
O’Neill BH: Phase II study of capecitabine, oxaliplatin, and cetuximab for
advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011, 4:78–83.
17. Bouma G, Imholz AL: Ileitis following capecitabine use. Ned Tijdschr
Geneeskd 2011, 155:A3064.
doi:10.1186/1746-1596-8-150
Cite this article as: Gurzu et al.: Lethal cardiotoxicity, steatohepatitis,
chronic pancreatitis, and acute enteritis induced by capecitabine and
oxaliplatin in a 36-year-old woman. Diagnostic Pathology 2013 8:150.
